Welcome to our dedicated page for Transmedics Group news (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on Transmedics Group stock.
TransMedics Group, Inc. (Nasdaq: TMDX) is a medical technology company that focuses on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. News about TransMedics often centers on its Organ Care System (OCS) warm perfusion platform, the National OCS Program (NOP), and initiatives aimed at increasing donor organ utilization.
Investors and healthcare professionals following TransMedics news can expect updates on financial results, including quarterly earnings announcements and related conference calls, as reflected in the company’s regular press releases and Form 8-K filings. Coverage also includes participation in major healthcare and investor conferences, where management presents the company’s strategy and discusses its transplant-focused technologies and services.
Another key news theme is TransMedics’ expansion of its logistics and service infrastructure. The company has disclosed the acquisition of fixed-wing aircraft for its National OCS Program and has announced a strategic collaboration with Mercedes-Benz Group AG to launch a dedicated organ transplantation ground transportation network in Italy using Mercedes-Benz V-Class vehicles. These developments are presented as part of a broader effort to build an integrated air and ground logistics network around the OCS platform.
TransMedics also issues news related to corporate growth, such as inducement equity grants under Nasdaq Listing Rule 5635(c)(4) and plans for a new global headquarters and integrated campus in Somerville, Massachusetts. For readers tracking TMDX, this news feed provides a centralized view of operational updates, regulatory and financial disclosures referenced in press releases, and developments in the company’s organ transplant technologies and services.
TransMedics (Nasdaq: TMDX) has received FDA conditional IDE approval to initiate its Next-Generation OCS ENHANCE Heart trial. The trial consists of two parts: Part A will evaluate prolonged heart perfusion using OCS™ Heart System, while Part B aims to demonstrate superiority of OCS Heart perfusion in donation after brain death (DBD) cases compared to static cold storage methods.
The groundbreaking trial is expected to include over 650 patients, potentially making it the largest heart preservation for transplant trial worldwide. The company plans to initiate both the ENHANCE Heart and DENOVO Lung trials in Q4 2025, with expectations for these trials to drive clinical adoption throughout 2026 and beyond.
TransMedics (NASDAQ: TMDX), a medical technology company focused on organ transplant therapy, has granted equity incentives to 14 new employees as employment inducements. The compensation package includes 21,458 non-qualified stock options with an exercise price of $105.24 per share and 14,283 restricted stock units (RSUs).
The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The RSUs will vest 25% annually over four years. Both grants require continued employment and were approved under Nasdaq Listing Rule 5635(c)(4) through the TransMedics Group, Inc. Inducement Plan.
TransMedics (NASDAQ: TMDX), a medical technology company specializing in organ transplant therapy, reported strong Q2 2025 financial results. The company achieved revenue of $157.4 million, marking a 38% increase year-over-year, and generated net income of $34.9 million ($0.92 per diluted share).
Key highlights include receiving conditional IDE approval for the Next-Gen OCS™ Lung trial, launching the NOP ACCESS™ digital ecosystem, and maintaining a strong 61% gross margin. The company has raised its full-year 2025 revenue guidance to $585-605 million, representing 35% growth at the midpoint compared to the previous guidance of $565-585 million.
TransMedics maintains a robust financial position with $400.6 million in cash as of June 30, 2025, and remains focused on achieving its target of 10,000 US NOP transplants by 2028.
TransMedics (NASDAQ: TMDX), a medical technology company specializing in organ transplant therapy solutions, announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The company's management team will deliver a presentation on Tuesday, August 12, 2025, at 11:30 a.m. ET at the InterContinental Boston Hotel.
Investors can access both the live and archived webcast of the fireside chat, along with the company's standard investor presentation, through the "Investors" section of TransMedics' website at investors.transmedics.com.
TransMedics (NASDAQ: TMDX), a medical technology company focused on organ transplant therapy, has scheduled its Second Quarter 2025 financial results announcement for July 30, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results. Investors can join via phone using specific dial-in numbers or access the webcast through TransMedics' investor relations website.
TransMedics (Nasdaq: TMDX), a medical technology company focused on organ transplant therapy, has announced its participation in two major investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference in Chicago on June 3 at 5:00 p.m. EST and participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 9 at 8:00 a.m. EST. Both presentations will be available via webcast on TransMedics' investor relations website.
TransMedics Group (Nasdaq: TMDX), a medical technology company focused on organ transplant therapy, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day. Investors can participate by dialing (844) 676-6010 (domestic) or (412) 634-6944 (international). A live and archived webcast will be available on the company's investor relations website.
TransMedics Group (TMDX) announced the granting of inducement awards to three new employees on March 28, 2025. The compensation package includes:
- 1,570 non-qualified stock options with an exercise price of $68.58 per share
- 1,043 restricted stock units (RSUs)
The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The RSUs will vest 25% annually over four years. Both grants require continued employment and were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) through the TransMedics Inducement Plan.
FAQ
What is the current stock price of Transmedics Group (TMDX)?
What is the market cap of Transmedics Group (TMDX)?
